Business Wire

GLEIF

14.4.2021 09:57:11 CEST | Business Wire | Press release

Share
GLEIF Welcomes Pioneering Advances by China Financial Certification Authority (CFCA) Which Pave the Way for Increased LEI Usage in Mass Market Digital Identity Products

The Global Legal Entity Identifier Foundation (GLEIF) has welcomed the first commercial demonstration of Legal Entity Identifiers (LEIs) embedded within digital certificates by the China Financial Certification Authority (CFCA). Simultaneously, GLEIF confirms that CFCA, which is a member of the GLEIF Certification Authorities (CA) Stakeholder Group, is the newest Validation Agent in the Global LEI System and the inaugural CA to sign up for the Validation Agent role.

These developments by CFCA follow the recent launch of the GLEIF CA Stakeholder Group, created as a platform for GLEIF to collaborate with CAs and Trust Service Providers (TSPs) on the coordination and promotion of a global approach to LEI usage across digital identity products. CFCA’s advances are significant because they are the earliest reported successes aligned to the direction of this industry initiative, which is aimed at achieving a critical mass of LEIs embedded within digital certificates.

Stephan Wolf, CEO of GLEIF comments: “This progress by CFCA on both fronts is very welcome as it moves us one step closer to broad LEI usage in digital certificates globally. Realizing the goal of universal LEI usage in digital identity products will be an important step in enhancing trust and creating innovation opportunities across private sector digital identity management applications. Digital certificates linked by an LEI to verified, regularly updated and freely available entity reference data held within the Global LEI System are easier to manage, aggregate and maintain. The result will be significant efficiencies and far less complexity for certificate owners and the provision of greater transparency for all users of the internet and participants within digital exchanges.”

CFCA demo: Using LEIs to link PDF digital certificates to entity reference data in the central GLEIF database

CFCA has become the first market participant to successfully demonstrate a commercial use case of LEIs being embedded in a digital certificate, specifically within the digital certificate issuance process for PDF documents. CFCA’s TrustSign® PDF software supports digital certificate signing and the demo shows the LEI displayed for users alongside certificate properties inside the software.

CFCA’s TrustSign® software digitally stamps a document with a Digital Business Stamp, which embeds an LEI in accordance with ISO 17442-2. When the document is opened and certificate properties are displayed, the LEI is shown and a link provided, via the GLEIF LEI Lookup API, to the trusted, free and easily accessible entity reference data associated with that LEI, held within the central GLEIF database.

Naijin Lu, from CFCA’s Strategic Development Department, comments: “Incorporating LEI into our digital identity products brings many benefits to certificate users, while being very helpful in constructing a digital identity ecosystem. By using GLEIF API for real-time online verification of LEI-related legal entity information, the advantages of digital certificate and LEI can be well integrated in the practice of digital identity to create a better digital identity authentication experience. We are excited to bring forward the first market-based demo of its kind, which proves that the combination of LEI and digital identity products has a bright future. In the future, we will actively explore other application scenarios of LEI in digital identification field, such as vLEI. “

Prior to CFCA’s demo, and in 2019 and 2020 consecutively, GLEIF had brought forward a Proof of Concept when it published its prior year reports with its LEI embedded within the digital certificates of GLEIF’s signing executive officers. Both instances were prior to the publication of ISO 17442-2 in August 2020 which standardized the process of embedding LEIs in digital certificates.

CFCA becomes a Validation Agent within the Global LEI System

In a complementary development which shows CFCA’s commitment to facilitating and promoting LEI issuance in digital certificates, the organization has become the first CA to become a Validation Agent in the Global LEI System. It partnered with a China based LEI issuer, China Financial Computerization Corp (CFCC), to enable customers to obtain LEIs and include them within CFCA products. This partnership, made possible under the GLEIF Validation Framework, provides CFCA customers with a ‘one-stop-shop’ for obtaining their LEIs alongside their identity authentication and information security services.

The Validation Agent Framework, announced by GLEIF in September 2020 , enables institutions to improve their customer experience, accelerate client lifecycle management and reduce costs by using ‘business-as-usual’, KYC onboarding procedures to facilitate LEI issuance for their clients.

Wolf concludes: “The swift and successful integration of the LEI into CFCA’s TrustSign® software is a hugely exciting innovation, which we hope will be a catalyst for other similar demos related to LEI usage in digital certificates to emerge. It shows what is possible thanks to ISO 17442-2 and demonstrates the LEI’s unique value in this important use case. GLEIF is happy to confirm CFCA as not only our newest Validation Agent within the Global LEI System, but also as the first CA to take up that role. Its partnership with CFCC has made that possible. As momentum builds for the LEI to be used outside of regulatory use cases, thanks to recognition of the opportunity and efficiencies it can offer to the private sector, provision of Validation Agent services by a wide range of key actors in the digital ID management and verification ecosystem will be critical to servicing scaled-up LEI demand and simplifying LEI issuance.

We are excited to learn more about CFCA’s advances through their engagement in the GLEIF CA Stakeholder Group. Their developments get this digital identity industry collaboration off to an incredibly strong start. We look forward to working with CFCA and all members of the CA Stakeholder Group as we jointly set out to advance trust and transparency within digital identity products.”

GLEIF welcomes CAs and TSPs to join and participate in the CA Stakeholder Group’s quarterly meetings. For more information or to join the group, please email info@gleif.org

- ENDS -

Full resolution images and logos can be downloaded via this link
https://www.gleif.org/en/newsroom/gleif-graphics-images

Relevant link
https://www.gleif.org/en

Source: Global Legal Entity Identifier Foundation, St. Alban-Vorstadt 5, 4052 Basel, Switzerland
Chairman of the Board: Steven Joachim, CEO: Stephan Wolf
Commercial-Register-No.: CHE-200.595.965, VAT-No.: CHE-200.595.965MWST
LEI: 506700GE1G29325QX363

http://bit.ly/1OXTYLo | http://bit.ly/1Me7uZx | GLEIF Blog: http://bit.ly/1LylXkn http://bit.ly/1LylXkn

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye